Radiopharmaceuticals should not be administered to patients who are pregnant unless the expected benefit to be gained outweighs the potential hazards.
Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.
Radiopharmaceuticals should not be administered to patients who are nursing mothers unless the expected benefit to be gained outweighs the potential hazards.
Since I-125 is excreted in human milk during lactation, formula-feedings should be substituted for breast-feedings.
Although the immunological properties of serum albumin are believed to be virtually unaltered by the iodinated process, there is a theoretical possibility that allergic reactions may occur in patients receiving additional doses a number of weeks after an initial dose.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
